Key result
Concomitant moderate-severe MR is not associated with worse outcomes in severe aortic stenosis.
Why the study?
The clinical significance of concomitant mitral regurgitation in patients with severe aortic stenosis has not been well addressed.
Does concomitant moderate/severe mitral regurgitation increase the risk of aortic valve-related death or heart failure hospitalization in patients with severe aortic stenosis?
Cohort (n=3,815)
Yes
Does concomitant moderate/severe mitral regurgitation increase the risk of aortic valve-related death or heart failure hospitalization in patients with severe aortic stenosis?
Hazard Ratio: 1.11 (95% CI 0.67–1.83)
Absolute Event Rate: 25.2% vs 14.4%
p-value: p=0.69
In patients with severe aortic stenosis, concomitant moderate or severe mitral regurgitation is not an independent predictor of aortic valve-related death or heart failure hospitalization, regardless of whether an initial AVR or conservative strategy is pursued.
BACKGROUND: The clinical significance of concomitant mitral regurgitation (MR) has not been well addressed in patients with severe aortic stenosis (AS). METHODS AND RESULTS: We analyzed 3,815 patients from a retrospective multicenter registry of severe AS in Japan (CURRENT AS registry). We compared the clinical outcomes between patients with moderate/severe MR and with none/mild MR according to the initial treatment strategy (initial aortic valve replacement [AVR] or conservative strategy). The primary outcome measure was a composite of aortic valve-related death or heart failure hospitalization. At baseline, moderate/severe MR was present in 227/1,197 (19%) patients with initial AVR strategy and in 536/2,618 (20%) patients with a conservative strategy. The crude cumulative 5-year incidence of the primary outcome measure was significantly higher in patients with moderate/severe MR than in those with none/mild MR, regardless of the initial treatment strategy (25.2% vs. 14.4%, P<0.001 in the initial AVR strategy, and 63.3% vs. 40.7%, P<0.001 in the conservative strategy). After adjusting confounders, moderate/severe MR was not independently associated with higher risk for the primary outcome measure in the initial AVR strategy (hazard ratio [HR] 1.11, 95% confidence interval [CI] 0.67-1.83, P=0.69), and in the conservative strategy (HR 1.13, 95% CI 0.93-1.37, P=0.22). CONCLUSIONS: Concomitant moderate/severe MR was not independently associated with higher risk for the primary outcome measure regardless of the initial treatment strategy.
No takes yet. Share an insight, caveat, or question.
Murai et al. (2021) conducted a cohort in Severe aortic stenosis (n=3,815). Moderate/severe mitral regurgitation vs. None/mild mitral regurgitation was evaluated on Composite of aortic valve-related death or heart failure hospitalization (HR 1.11, 95% CI 0.67-1.83, p=0.69). Concomitant moderate/severe mitral regurgitation was not independently associated with a higher risk of aortic valve-related death or heart failure hospitalization in patients with severe aortic stenosis, regardless of initial treatment strategy (AVR HR 1.11; conservative HR 1.13).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: